- Home
- XP vs BMRN Comparison
XP vs BMRN Comparison
Compare XP & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | BMRN |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.5B |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | XP | BMRN |
|---|---|---|
| Price | $17.54 | $53.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 19 |
| Target Price | $22.40 | ★ $88.42 |
| AVG Volume (30 Days) | ★ 8.8M | 2.9M |
| Earning Date | 11-17-2025 | 10-27-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | 18.53 | ★ 59.53 |
| EPS | 1.76 | ★ 2.68 |
| Revenue | ★ $3,229,174,949.00 | $3,094,001,000.00 |
| Revenue This Year | $17.71 | $13.39 |
| Revenue Next Year | $13.05 | $7.57 |
| P/E Ratio | ★ $9.92 | $19.89 |
| Revenue Growth | 8.33 | ★ 12.39 |
| 52 Week Low | $10.82 | $50.76 |
| 52 Week High | $20.64 | $73.51 |
Technical Indicators
Market Signals| Indicator | XP | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 46.21 |
| Support Level | $17.52 | $52.55 |
| Resistance Level | $20.06 | $54.33 |
| Average True Range (ATR) | 0.71 | 1.24 |
| MACD | -0.19 | -0.17 |
| Stochastic Oscillator | 5.95 | 19.23 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.